Medipal Holdings (7459) · InitiativeFirst stated

Building a Regenerative Medicine Value Chain Through an Investment in オリヅルセラピューティクス

First written in FY2022-Q2. . Latest entry: FY2022-Q2.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Creating New Businesses through Investments in Testing and Diagnostic Device Companies and Regenerative Medicine CompaniesA theme 7 companies write about · 0 as a headwind · 10 as a tailwind

3 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Full recordFilings, disclosures and news, newest first

FY2022-Q2First statedAnnual report
「In August of the same year, the Company subscribed to a third-party allocation of shares by オリヅルセラピューティクス株式会社 (Sakyo-ku, Kyoto), which develops regenerative medicine products using cell transplantation. The Company will support the development and commercialization of innovative therapies using iPS cells originating in Japan, seek to expand the range of products it handles in the future regenerative medicine field, and work with the company to build an optimal value chain for regenerative medicine by combining the knowledge, experience and expertise of both companies.」
In August 2021, the Company subscribed to a third-party allocation of shares by オリヅルセラピューティクス, which develops regenerative medicine products, and began initiatives to support the development and commercialization of iPS cell-based therapies and build a regenerative medicine value chain.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

Medipal Holdings's next results are scheduled for 2026-11-05. Read the earnings preview

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.